» Articles » PMID: 11570877

Insulin Regulation of Gene Expression Through the Forkhead Transcription Factor Foxo1 (Fkhr) Requires Kinases Distinct from Akt

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2001 Sep 26
PMID 11570877
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin inhibits expression of certain liver genes through the phosphoinositol (PI) 3-kinase/Akt pathway. However, whether Akt activity is both necessary and sufficient to mediate these effects remains controversial. The forkhead proteins (Foxo1, Foxo3, and Foxo4, previously known as Fkhr or Afx) are transcriptional enhancers, the activity of which is inhibited by insulin through phosphorylation-dependent translocation and nuclear exclusion. Others and we have previously shown that the forkhead protein Foxo1 is phosphorylated at three different sites: S(253), T(24), and S(316). We have also shown that T(24) fails to be phosphorylated in hepatocytes lacking insulin receptors, and we have suggested that this residue is targeted by a kinase distinct from Akt. In this study, we have further analyzed the ability of Akt to phosphorylate different Foxo1 sites in control and insulin receptor-deficient hepatocytes. Expression of a dominant negative Akt (Akt-AA) in control hepatocytes led to complete inhibition of endogenous Akt, but failed to inhibit Foxo1 T(24) phosphorylation and, consequently, insulin suppression of IGFBP-1 promoter activity. Conversely, expression of a constitutively active Akt (Akt-Myr) in insulin receptor-deficient hepatocytes led to an overall increase in the level of Foxo1 phosphorylation, but failed to induce T(24) and S(316) phosphorylation. These data indicate that the Foxo1 T(24) and S(316) kinases are distinct from Akt, and suggest that the pathways required for insulin regulation of hepatic gene expression diverge downstream of PI 3-kinase.

Citing Articles

Noncanonical CDK4 signaling rescues diabetes in a mouse model by promoting β cell differentiation.

Stamateris R, Landa-Galvan H, Sharma R, Darko C, Redmond D, Rane S J Clin Invest. 2023; 133(18).

PMID: 37712417 PMC: 10503800. DOI: 10.1172/JCI166490.


Human and mouse muscle transcriptomic analyses identify insulin receptor mRNA downregulation in hyperinsulinemia-associated insulin resistance.

Cen H, Hussein B, Botezelli J, Wang S, Zhang J, Noursadeghi N FASEB J. 2021; 36(1):e22088.

PMID: 34921686 PMC: 9255858. DOI: 10.1096/fj.202100497RR.


Forkhead Box Protein O1: Functional Diversity and Post-Translational Modification, a New Therapeutic Target?.

Zhang X, Jiang L, Liu H Drug Des Devel Ther. 2021; 15:1851-1860.

PMID: 33976536 PMC: 8106445. DOI: 10.2147/DDDT.S305016.


Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Bustad H, Kallio J, Vorland M, Fiorentino V, Sandberg S, Schmitt C Int J Mol Sci. 2021; 22(2).

PMID: 33445488 PMC: 7827610. DOI: 10.3390/ijms22020675.


Tissue-Specific Metabolic Regulation of FOXO-Binding Protein: FOXO Does Not Act Alone.

Kodani N, Nakae J Cells. 2020; 9(3).

PMID: 32182991 PMC: 7140670. DOI: 10.3390/cells9030702.